Evolus vs Organogenesis
EOLS and ORGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EOLS and ORGO compare
Evolus is the larger company, worth 4.4 times as much as Organogenesis ($460M against $104M).
Evolus grew revenue faster over the last twelve months (13.9% versus −24.3% for Organogenesis).
Evolus keeps more of each dollar of sales as profit, with a net margin of −9.6% compared with −38.4% at Organogenesis.
Organogenesis scores higher on the StockData Score (8 against 6 for Evolus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EOLS | ORGO |
|---|---|---|
| Size and price | ||
| Market cap | $460M | $104M |
| Share price | $6.96 | $0.810 |
| Change, 1 year | −4.7% | −87.5% |
| Change, 5 years | 9.1% | −91.8% |
| Beta (5Y) | 1.13 | 1.14 |
| Employees | 334 | 854 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 1 | 1 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× | 0.3× (better) |
| P/B | – | 0.9× |
| FCF yield | −1.1% | −0.06% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.9% (better) | −24.3% |
| Revenue growth, 5Y average | 39.4% (better) | 10.8% |
| Net income growth (TTM) | – | −13568% |
| EPS growth, 5Y average | – | 0.00% |
| Profitability | ||
| Gross margin | 66.4% | – |
| Operating margin | −4.8% (better) | −24.5% |
| Net margin | −9.6% (better) | −38.4% |
| FCF margin | −1.5% | −0.02% (better) |
| Return on equity | – | −72.2% |
| Return on invested capital | −16.3% (better) | −47.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1.0× | – |
| Current ratio | 1.42 | 3.32 (better) |
| Altman Z-score | −1.34 | 0.44 (better) |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.0% | 53.2% |
| Held by insiders | 4.1% | – |
| Insider net buying, 12 months | −$1.8M | −$988K (better) |
| Short interest, % of float | 9.5% | – |
Go deeper
- EOLS stock overview
- EOLS income statement
- EOLS valuation and score
- ORGO stock overview
- ORGO income statement
- ORGO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.